Core Insights - CVS Health reported quarterly earnings of $1.6 per share, exceeding the Zacks Consensus Estimate of $1.36 per share, and showing an increase from $1.09 per share a year ago, resulting in an earnings surprise of +17.65% [1] - The company achieved revenues of $102.87 billion for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 4.66% and up from $95.43 billion year-over-year [2] - CVS Health shares have increased by approximately 83.1% since the beginning of the year, significantly outperforming the S&P 500's gain of 17.2% [3] Earnings Outlook - The future performance of CVS Health's stock will largely depend on management's commentary during the earnings call and the company's earnings outlook [4] - The current consensus EPS estimate for the upcoming quarter is $0.95 on revenues of $100.48 billion, and for the current fiscal year, it is $6.36 on revenues of $392.28 billion [7] Industry Context - The Medical Services industry, to which CVS Health belongs, is currently ranked in the top 39% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8]

Core Viewpoint - Sera Prognostics, Inc. reported a quarterly loss of $0.25 per share, slightly worse than the Zacks Consensus Estimate of a loss of $0.23, indicating a negative earnings surprise of -8.70% [1] Financial Performance - The company posted revenues of $0.02 million for the quarter ended December 2024, missing the Zacks Consensus Estimate by 20%, and a decline from $0.04 million in the same quarter last year [2] - Over the last four quarters, Sera Prognostics has consistently failed to meet consensus EPS and revenue estimates [2] Stock Performance - Sera Prognostics shares have declined approximately 49.9% since the beginning of the year, contrasting with the S&P 500's decline of -4.5% [3] - The current Zacks Rank for Sera Prognostics is 4 (Sell), indicating expectations of underperformance in the near future [6] Earnings Outlook - The consensus EPS estimate for the upcoming quarter is -$0.24 on revenues of $0.1 million, and for the current fiscal year, it is -$0.98 on revenues of $3.5 million [7] - The trend of estimate revisions for Sera Prognostics has been unfavorable leading up to the earnings release [6] Industry Context - The Medical Services industry, to which Sera Prognostics belongs, is currently ranked in the top 29% of over 250 Zacks industries, suggesting a relatively strong industry performance [8]